Massobrio, R.; Attianese, D.; Testi, A.; Pascotto, M.; Campigotto, B.; Garulli, C.; Pace, L.; Ricotti, A.; Fuso, L.; Ferrero, A.
Symptom Monitoring in Ovarian Cancer Patients Treated with PARP Inhibitors: Agreement Between Physician- and Patient-Reported Toxicities Using PRO-CTCAE. Cancers 2026, 18, 650.
https://doi.org/10.3390/cancers18040650
AMA Style
Massobrio R, Attianese D, Testi A, Pascotto M, Campigotto B, Garulli C, Pace L, Ricotti A, Fuso L, Ferrero A.
Symptom Monitoring in Ovarian Cancer Patients Treated with PARP Inhibitors: Agreement Between Physician- and Patient-Reported Toxicities Using PRO-CTCAE. Cancers. 2026; 18(4):650.
https://doi.org/10.3390/cancers18040650
Chicago/Turabian Style
Massobrio, Roberta, Daniela Attianese, Alessandra Testi, Maria Pascotto, Beatrice Campigotto, Claudia Garulli, Luca Pace, Andrea Ricotti, Luca Fuso, and Annamaria Ferrero.
2026. "Symptom Monitoring in Ovarian Cancer Patients Treated with PARP Inhibitors: Agreement Between Physician- and Patient-Reported Toxicities Using PRO-CTCAE" Cancers 18, no. 4: 650.
https://doi.org/10.3390/cancers18040650
APA Style
Massobrio, R., Attianese, D., Testi, A., Pascotto, M., Campigotto, B., Garulli, C., Pace, L., Ricotti, A., Fuso, L., & Ferrero, A.
(2026). Symptom Monitoring in Ovarian Cancer Patients Treated with PARP Inhibitors: Agreement Between Physician- and Patient-Reported Toxicities Using PRO-CTCAE. Cancers, 18(4), 650.
https://doi.org/10.3390/cancers18040650
